Background: In the CYD14 and CYD15 Phase 3 trials of the CYD-TDV dengue vaccine, estimated vaccine efficacy (VE) against symptomatic, virologically confirmed dengue (VCD) occurring between months 13 and 25 was 56.5% and 60.8%, respectively. Methods: Neutralizing antibody titers to the 4 dengue serotypes in the CYD-TDV vaccine insert were measured at month 13 in a randomly sampled immunogenicity subcohort and in all VCD cases through month 25 (2848 vaccine, 1574 placebo) and studied for their association with VCD and with the level of VE to prevent VCD. Results: For each trial and serotype, vaccinees with higher month 13 titer to the serotype had significantly lower risk of VCD with that serotype (hazard ratios, 0.19-0.43 per 10-fold increase). Moreover, for each trial, vaccinees with higher month 13 average titer to the 4 serotypes had significantly higher VE against VCD of any serotype (P < .001). Conclusions: Neutralizing antibody titers postdose 3 correlate with CYD-TDV VE to prevent dengue. High titers associate with high VE for all serotypes, baseline serostatus groups, age groups, and both trials. However, lowest titers do not fully correspond to zero VE, indicating that other factors influence VE.
Background: In the CYD14 and CYD15 Phase 3 trials of the CYD-TDV dengue vaccine, estimated vaccine efficacy (VE) against symptomatic, virologically confirmed dengue (VCD) occurring between months 13 and 25 was 56.5% and 60.8%, respectively. Methods: Neutralizing antibody titers to the 4 dengue serotypes in the CYD-TDV vaccine insert were measured at month 13 in a randomly sampled immunogenicity subcohort and in all VCD cases through month 25 (2848 vaccine, 1574 placebo) and studied for their association with VCD and with the level of VE to prevent VCD. Results: For each trial and serotype, vaccinees with higher month 13 titer to the serotype had significantly lower risk of VCD with that serotype (hazard ratios, 0.19-0.43 per 10-fold increase). Moreover, for each trial, vaccinees with higher month 13 average titer to the 4 serotypes had significantly higher VE against VCD of any serotype (P < .001). Conclusions: Neutralizing antibody titers postdose 3 correlate with CYD-TDV VE to prevent dengue. High titers associate with high VE for all serotypes, baseline serostatus groups, age groups, and both trials. However, lowest titers do not fully correspond to zero VE, indicating that other factors influence VE.
Authors: Sri Rezeki Hadinegoro; Jose Luis Arredondo-García; Maria Rosario Capeding; Carmen Deseda; Tawee Chotpitayasunondh; Reynaldo Dietze; H I Hj Muhammad Ismail; Humberto Reynales; Kriengsak Limkittikul; Doris Maribel Rivera-Medina; Huu Ngoc Tran; Alain Bouckenooghe; Danaya Chansinghakul; Margarita Cortés; Karen Fanouillere; Remi Forrat; Carina Frago; Sophia Gailhardou; Nicholas Jackson; Fernando Noriega; Eric Plennevaux; T Anh Wartel; Betzana Zambrano; Melanie Saville Journal: N Engl J Med Date: 2015-07-27 Impact factor: 91.245
Authors: Timothy P Endy; Ananda Nisalak; Supamit Chunsuttitwat; David W Vaughn; Sharone Green; Francis A Ennis; Alan L Rothman; Daniel H Libraty Journal: J Infect Dis Date: 2004-03-01 Impact factor: 5.226
Authors: Tatyana M Timiryasova; Matthew I Bonaparte; Ping Luo; Rebecca Zedar; Branda T Hu; Stephen W Hildreth Journal: Am J Trop Med Hyg Date: 2013-03-04 Impact factor: 2.345
Authors: Brett M Forshey; Robert C Reiner; Sandra Olkowski; Amy C Morrison; Angelica Espinoza; Kanya C Long; Stalin Vilcarromero; Wilma Casanova; Helen J Wearing; Eric S Halsey; Tadeusz J Kochel; Thomas W Scott; Steven T Stoddard Journal: PLoS Negl Trop Dis Date: 2016-02-05
Authors: Peter B Gilbert; Ying Huang; Michal Juraska; Zoe Moodie; Youyi Fong; Alexander Luedtke; Yingying Zhuang; Jason Shao; Lindsay N Carpp; Nicholas Jackson; Laurent Chambonneau; Alain Bouckenooghe; Betzana Zambrano; Carina Frago; Sophie Pallardy; Fernando Noriega Journal: Am J Trop Med Hyg Date: 2019-07 Impact factor: 2.345
Authors: Ellen Young; Robert H Carnahan; Daniela V Andrade; Nurgun Kose; Rachel S Nargi; Ethan J Fritch; Jennifer E Munt; Michael P Doyle; Laura White; Thomas J Baric; Mark Stoops; Aravinda DeSilva; Longping V Tse; David R Martinez; Deanna Zhu; Stefan Metz; Marcus P Wong; Diego A Espinosa; Magelda Montoya; Scott B Biering; Soila Sukulpolvi-Petty; Guillermina Kuan; Angel Balmaseda; Michael S Diamond; Eva Harris; James E Crowe; Ralph S Baric Journal: Cell Host Microbe Date: 2020-05-13 Impact factor: 21.023
Authors: Michal Juraska; Craig A Magaret; Jason Shao; Lindsay N Carpp; Andrew J Fiore-Gartland; David Benkeser; Yves Girerd-Chambaz; Edith Langevin; Carina Frago; Bruno Guy; Nicholas Jackson; Kien Duong Thi Hue; Cameron P Simmons; Paul T Edlefsen; Peter B Gilbert Journal: Proc Natl Acad Sci U S A Date: 2018-08-20 Impact factor: 11.205
Authors: Stephen J Popper; Fiona R Strouts; Janet C Lindow; Henry K Cheng; Magelda Montoya; Angel Balmaseda; Anna P Durbin; Stephen S Whitehead; Eva Harris; Beth D Kirkpatrick; David A Relman Journal: J Infect Dis Date: 2018-11-05 Impact factor: 5.226
Authors: Kirsten S Vannice; Annelies Wilder-Smith; Alan D T Barrett; Kalinka Carrijo; Marco Cavaleri; Aravinda de Silva; Anna P Durbin; Tim Endy; Eva Harris; Bruce L Innis; Leah C Katzelnick; Peter G Smith; Wellington Sun; Stephen J Thomas; Joachim Hombach Journal: Vaccine Date: 2018-03-07 Impact factor: 3.641